China NT Pharma Revises Terms of Medical Device Acquisition and Extends Long Stop Date

China NT Pharma Group Co., Ltd. ( (HK:1011) ) has shared an update.

China NT Pharma Group has signed a supplemental agreement to revise the payment terms of its previously announced acquisition of 100% of the issued shares in certain target companies, which will be settled through the issuance of consideration shares under a specific mandate. The consideration of RMB116.2 million will now be fully satisfied by allotting and issuing consideration shares to the sellers on a pro rata basis within 30 days after both the successful registration and granting of a medical device registration certificate for the company’s Portable Digital X-Ray Diagnostic Robot System in Zhejiang Province and completion of the deal, while the long stop date for closing has been extended to 28 April 2026, aligning the timetable and conditions of the transaction more closely with regulatory approval milestones and potentially affecting the pace of its expansion into the medical device segment.

The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.

More about China NT Pharma Group Co., Ltd.

China NT Pharma Group Company Limited is a Hong Kong-listed pharmaceutical group engaged in the broader healthcare sector, with activities that include medical technology and devices. The company is expanding into advanced diagnostic equipment, such as a Portable Digital X-Ray Diagnostic Robot System, indicating a focus on innovative medical solutions in the Chinese healthcare market.

Average Trading Volume: 535,101

Technical Sentiment Signal: Buy

Current Market Cap: HK$559.6M

See more data about 1011 stock on TipRanks’ Stock Analysis page.